Save time and jump to the most important pieces.
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update CallDate: Tuesday, September 24, 2024Time: 8:30 am ET We
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update CallDate: Wednesday, April 10, 2024Time: 8:30 am EDTWebcast URL
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides. Webcast Access: Date: Monday, December 11, 2023Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg Register for Teleconference:
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering of legacy assets underway as Company transitions to focused RNA delivery technology providerAchieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debtFinished year with shareholders' equity of CHF 6.5 million, improved by CHF 14.8 million HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond th
Management will host an investor conference call today, May 16th, at 8 a.m. EasternCompany is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023Filed IND submission with FDA for AM-125 in acute vestibular syndrome‘Showcase' RNA development programs AM-401 and AM-411 progressing in KRAS-driven cancers and rheumatoid arthritis, targeting INDs in 2024Divestiture or partnering of legacy assets remains a key strategic focusTop-line data from full NASAR trial with Bentrio in seasonal allergic rhinitis expected in the second quarterHAMILTON, BERMUDA / ACCESSWIRE / M
Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern.Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliverEstablished new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal spray and successfully established distribution partners covering more than 20 countries so far.Reported completion of enrollment into Bentrio™ house dust mite clinical trial with expected top-line results planned for 2Q-22, and initiation of "COVAMID" clinical trial in acute COVID-19.Completed patient enrollment in Part B of Phase 2 ‘TRAVERS' clinical trial evaluating AM-125 in acute vertigo; expec
Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysmAltamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wallPositive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica's Bentrio® nasal
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new R&D facilities Publications by independent research groups provide fresh evidence of effective mRNA delivery to extrahepatic targets Major territory expansion with two distribution partners for Bentrio® Financial results presented for first time in US dollars rather than Swiss francs Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)